HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway

Free Radical Biology and Medicine

Volumn 70, Issue , 2014, Pages 194-203

  Ni, Zhenhong ^a   Wang, Bin ^a   Dai, Xufang ^b   Ding, Wen ^a   Yang, Ting ^a   Li, Xinzhe ^a   Jason, Seth ^c   Xu, Liang ^c   Lian, Jiqin ^a   He, Fengtian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

ABT 737; Apoptosis; Autophagy; Bcl 2; Free radicals; HCC; JNK; ROS

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BECLIN 1; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; ABT-737; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; BIOACCUMULATION; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL LEVEL; CELL PROTECTION; CELL STIMULATION; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOSOL; DISSOCIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

APOPTOSIS; AUTOPHAGY; BIPHENYL COMPOUNDS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 84897846473     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.02.012     Document Type: Article

References (61)

1. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
2. M. Sherman Epidemiology of hepatocellular carcinoma Oncology 78 Suppl. 1 2010 7 10
3. S. Tanaka, and S. Arii Molecular targeted therapies in hepatocellular carcinoma Semin. Oncol. 39 2012 486 492
4. L. Zender, M.S. Spector, W. Xue, P. Flemming, C. Cordon-Cardo, J. Silke, S.T. Fan, J.M. Luk, M. Wigler, G.J. Hannon, D. Mu, R. Lucito, S. Powers, and S.W. Lowe Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach Cell 125 2006 1253 1267
5. B. Levine, S. Sinha, and G. Kroemer Bcl-2 family members: dual regulators of apoptosis and autophagy Autophagy 4 2008 600 606
6. M.H. Kang, and C.P. Reynolds Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 15 2009 1126 1132
7. Y. Yang, J. Zhu, H. Gou, D. Cao, M. Jiang, and M. Hou Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC) Med. Oncol. 28 2011 796 803
8. E. Chun, and K.-Y. Lee Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 315 2004 771 779
9. K.F. Whitecross, A.E. Alsop, L.A. Cluse, A. Wiegmans, K.M. Banks, C. Coomans, M.J. Peart, A. Newbold, R.K. Lindemann, and R.W. Johnstone Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors Blood 113 2009 1982 1991
10. D.J. Fitzgerald, E. Moskatel, G. Ben-Josef, R. Traini, T. Tendler, A. Sharma, A. Antignani, F. Mussai, A. Wayne, R.J. Kreitman, and I. Pastan Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737 Leuk. Lymphoma 52 Suppl. 2 2011 79 81
11. H. Hikita, T. Takehara, S. Shimizu, T. Kodama, M. Shigekawa, K. Iwase, A. Hosui, T. Miyagi, T. Tatsumi, H. Ishida, W. Li, T. Kanto, N. Hiramatsu, and N. Hayashi The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib Hepatology 52 2010 1310 1321
12. H. Zhu, W. Yang, L.J. He, W.J. Ding, L. Zheng, S.D. Liao, P. Huang, W. Lu, Q.J. He, and B. Yang Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells PLoS One 7 2012 e52333
13. S.J. Dixon, and B.R. Stockwell The role of iron and reactive oxygen species in cell death Nat. Chem. Biol. 10 2013 9 17
14. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discovery 8 2009 579 591
15. M. Tien Kuo, and N. Savaraj Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers Mol. Carcinog. 45 2006 701 709
16. P. Cheng, Z. Ni, X. Dai, B. Wang, W. Ding, A.R. Smith, L. Xu, D. Wu, F. He, and J. Lian The novel BH-3 mimetic apogossypolone induces Beclin-1-and ROS-mediated autophagy in human hepatocellular cells Cell Death Dis. 4 2013
17. Y. Kabeya, N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, and T. Yoshimori LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing EMBO J. 19 2000 5720 5728
18. J. Lian, Z. Ni, X. Dai, C. Su, A.R. Smith, L. Xu, and F. He Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation Mol. Cancer Ther. 11 2012 416 426
19. F. Vogt, J. Lieber, A. Dewerth, A. Hoh, J. Fuchs, and S. Armeanu-Ebinger BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells Exp. Cell Res. 319 2013 1443 1450
20. C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 2013 714 726
21. J.-H. Jang, and Y.-J. Surh Potentiation of cellular antioxidant capacity by Bcl-2: implications for its antiapoptotic function Biochem. Pharmacol. 66 2003 1371 1379
22. A.N. Howard, K.A. Bridges, R.E. Meyn, and J. Chandra ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress Cancer Chemother. Pharmacol. 65 2009 41 54
23. K. Sun, X. Xie, Y. Liu, Z. Han, X. Zhao, N. Cai, S. Zhang, J. Song, and L. Wei Autophagy lessens ischemic liver injury by reducing oxidative damage Cell Biosci. 3 2013 26
24. G.V. Helgason, T.L. Holyoake, and K.M. Ryan Role of autophagy in cancer prevention, development and therapy Essays Biochem. 55 2013 133 151
25. P. Maycotte, and A. Thorburn Autophagy and cancer therapy Cancer Biol. Ther. 11 2011 127 137
26. M. Hoyer-Hansen, and M. Jaattela Autophagy: an emerging target for cancer therapy Autophagy 4 2008 574 580
27. C.G. Ferreira, M. Epping, F.A. Kruyt, and G. Giaccone Apoptosis: target of cancer therapy Clin. Cancer Res. 8 2002 2024 2034
28. D.E. Fisher Apoptosis in cancer therapy: crossing the threshold Cell 78 1994 539 542
29. R.T. Marquez, and L. Xu Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch Am. J. Cancer Res. 2 2012 214 221
30. S. Pattingre, A. Tassa, X. Qu, R. Garuti, X.H. Liang, N. Mizushima, M. Packer, M.D. Schneider, and B. Levine Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy Cell 122 2005 927 939
31. H. Schlagbauer-Wadl, G. Klosner, E. Heere-Ress, S. Waltering, I. Moll, K. Wolff, H. Pehamberger, and B. Jansen Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice J. Invest. Dermatol. 114 2000 725 730
32. A.Z. Badros, O. Goloubeva, A.P. Rapoport, B. Ratterree, N. Gahres, B. Meisenberg, N. Takebe, M. Heyman, J. Zwiebel, H. Streicher, C.D. Gocke, D. Tomic, J.A. Flaws, B. Zhang, and R.G. Fenton Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients J. Clin. Oncol. 23 2005 4089 4099
33. J.M. Adams, and S. Cory Bcl-2-regulated apoptosis: mechanism and therapeutic potential Curr. Opin. Immunol. 19 2007 488 496
34. Z. Ni, X. Dai, B. Wang, W. Ding, P. Cheng, L. Xu, J. Lian, and F. He Natural Bcl-2 inhibitor (-)-gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma Leuk. Lymphoma 54 2013 2263 2268
35. J.T. Zhong, Y. Xu, H.W. Yi, J. Su, H.M. Yu, X.Y. Xiang, X.N. Li, Z.C. Zhang, and L.K. Sun The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells Cancer Lett. 323 2012 180 187
36. S.A. Malik, S. Shen, G. Marino, A. BenYounes, M.C. Maiuri, and G. Kroemer BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades Autophagy 7 2011 914 916
37. J. Lian, X. Wu, F. He, D. Karnak, W. Tang, Y. Meng, D. Xiang, M. Ji, T.S. Lawrence, and L. Xu A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum Cell Death Differ. 18 2011 60 71
38. R.L. Zinn, E.E. Gardner, I. Dobromilskaya, S. Murphy, L. Marchionni, C.L. Hann, and C.M. Rudin Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer Mol. Cancer 12 2013 16
39. S.A. Malik, I. Orhon, E. Morselli, A. Criollo, S. Shen, G. Marino, A. BenYounes, P. Benit, P. Rustin, M.C. Maiuri, and G. Kroemer BH3 mimetics activate multiple pro-autophagic pathways Oncogene 30 2011 3918 3929
40. N. Chen, and V. Karantza Autophagy as a therapeutic target in cancer Cancer Biol. Ther. 11 2011 157 168
41. M.F. van Delft, A.H. Wei, K.D. Mason, C.J. Vandenberg, L. Chen, P.E. Czabotar, S.N. Willis, C.L. Scott, C.L. Day, S. Cory, J.M. Adams, A.W. Roberts, and D.C. Huang The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 10 2006 389 399
42. M.S. Davids, and A. Letai Targeting the B-cell lymphoma/leukemia 2 family in cancer J. Clin. Oncol. 30 2012 3127 3135
43. C.L. Hann, V.C. Daniel, E.A. Sugar, I. Dobromilskaya, S.C. Murphy, L. Cope, X. Lin, J.S. Hierman, D.L. Wilburn, D.N. Watkins, and C.M. Rudin Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer Cancer Res. 68 2008 2321 2328
44. C. Touzeau, C. Dousset, L. Bodet, P. Gomez-Bougie, S. Bonnaud, A. Moreau, P. Moreau, C. Pellat-Deceunynk, M. Amiot, and S. Le Gouill ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents Clin. Cancer Res. 17 2011 5973 5981
45. T. Klymenko, M. Brandenburg, C. Morrow, C. Dive, and G. Makin The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells Mol. Cancer Ther. 10 2011 2373 2383
46. B. Zhivotovsky, and V.O. Kaminskyy Free radicals in crosstalk between autophagy and apoptosis Antioxid. Redox Signaling 2013 (in press), http://dx.doi.org/10.1089/ars.2013.5746
47. I.C. Low, J. Kang, and S. Pervaiz Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells Antioxid. Redox Signaling 15 2011 2975 2987
48. H.M. Wilkins, K. Marquardt, L.H. Lash, and D.A. Linseman Bcl-2 is a novel interacting partner for the 2-oxoglutarate carrier and a key regulator of mitochondrial glutathione Free Radic. Biol. Med. 52 2012 410 419
49. A.K. Zimmermann, F.A. Loucks, E.K. Schroeder, R.J. Bouchard, K.L. Tyler, and D.A. Linseman Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria J. Biol. Chem. 282 2007 29296 29304
50. Z.X. Chen, and S. Pervaiz Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2 Cell Death Differ 17 2010 408 420
51. D.M. Hockenbery, Z.N. Oltvai, X.M. Yin, C.L. Milliman, and S.J. Korsmeyer Bcl-2 functions in an antioxidant pathway to prevent apoptosis Cell 75 1993 241 251
52. J.H. Jang, and Y.J. Surh Bcl-2 attenuation of oxidative cell death is associated with up-regulation of gamma-glutamylcysteine ligase via constitutive NF-kappaB activation J. Biol. Chem 279 2004 38779 38786
53. I.C. Low, Z.X. Chen, and S. Pervaiz Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells Antioxid. Redox Signaling 13 2010 807 819
54. D.W. Voehringer BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity Free Radic. Biol. Med. 27 1999 945 950
55. A. Hochman, H. Sternin, S. Gorodin, S. Korsmeyer, I. Ziv, E. Melamed, and D. Offen Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice J. Neurochem. 71 1998 741 748
56. J. Liu, and A. Lin Role of JNK activation in apoptosis: a double-edged sword Cell Res. 15 2005 36 42
57. Y. Wei, S. Pattingre, S. Sinha, M. Bassik, and B. Levine JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy Mol. Cell 30 2008 678 688
58. M. Kelkel, C. Cerella, F. Mack, T. Schneider, C. Jacob, M. Schumacher, M. Dicato, and M. Diederich ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis Carcinogenesis 33 2012 2162 2171
59. X.Q. Zhang, X.F. Huang, X.B. Hu, Y.H. Zhan, Q.X. An, S.M. Yang, A.J. Xia, J. Yi, R. Chen, S.J. Mu, and D.C. Wu Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro Asian J. Androl. 12 2010 697 708
60. H. Mei, Z. Lin, Y. Wang, G. Wu, and Y. Song Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer Neoplasma 61 2014 186 192
61. A. Saleem, D. Dvorzhinski, U. Santanam, R. Mathew, K. Bray, M. Stein, E. White, and R.S. DiPaola Effect of dual inhibition of apoptosis and autophagy in prostate cancer Prostate 72 2012 1374 1381